Biotie Therapies Oyj : Biotie reports top-line data from clinical study with nepicastat (SYN117) in post-traumatic stress

 Biotie Therapies Oyj : Biotie reports top-line data from clinical study with
            nepicastat (SYN117) in post-traumatic stress disorder

December 2012 at 9:00 a.m

Biotie reports top-line data from clinical study with nepicastat (SYN117) in
post-traumatic stress disorder

Biotie today reported top-line data from a Phase 2 study evaluating its
dopamine beta hydroxylase inhibitor nepicastat (SYN117) in combat veterans
suffering from post-traumatic stress disorder (PTSD). The study was funded by
the U.S. Department of Defense and conducted as an Investigator-initiated
study in the United States using clinical trial material supplied by Biotie.

Treatment with nepicastat was not effective in relieving PTSD-associated
symptoms when compared to placebo. Nepicastat was generally well tolerated.

"We are disappointed with the results of this trial and will work with the
study investigators to analyze and understand the data in more detail before
deciding on next steps with nepicastat in PTSD", said Timo Veromaa, President
and CEO of Biotie. "Independent of these results, we will continue to develop
nepicastat in cocaine dependence in partnership with the U.S. National
Institute of Drug Abuse (NIDA). We expect the first patients to be enrolled
into a Phase 2 study in Q1 2013."

Turku, 27 December, 2012

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:
Dr. Stephen Bandak, Chief Medical Officer
tel. +1 650 296 0946 (Pacific Time zone), email:

Virve Nurmi, Investor Relations Manager
tel. +358 2 274 8900, e-mail:

NASDAQ OMX Helsinki Ltd
Main Media

ABOUT THE STUDY ( identifier: NCT00659230)

The completed Phase 2 study was a randomized, placebo-controlled, double-blind
study conducted in 100 combat veterans fulfilling diagnostic criteria for
PTSD. It was conducted at 4 VA Medical Centers in the United States, with Dr.
Lori Davis from Tuscaloosa VA Medical Center as the Principal Investigator.

The subjects were randomized in a 1:1 ratio to receive either 120 mg/day
nepicastat or matching placebo for 6 weeks under double-blind conditions.
Thereafter, subjects could continue on open-label study drug for an additional
8 weeks.

Efficacy was evaluated with the Clinician-Administered PTSD Scale (CAPS); the
primary efficacy variable was the CAPS hyperarousal subscale (CAPS-D). Safety
and tolerability were assessed with standard methods, including adverse event
inquiries and laboratory analyses.


Nepicastat is an orally administered, potent and selective inhibitor of the
enzyme dopamine beta hydroxylase (DBH), the enzyme responsible for the
conversion of dopamine into norepinephrine. The compound has demonstrated
potential as a treatment for cocaine dependence and PTSD.

Nepicastat was licensed from Roche in 2007.


Biotie is a specialized drug development company focused on the development of
drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's
disease, Alzheimer's disease and other cognitive disorders, alcohol and drug
dependence (addiction) and post-traumatic stress disorder), and inflammatory
and fibrotic liver disease. The company has a strong and balanced development
portfolio with several innovative small molecule and biological drug
candidates at different stages of clinical development. Biotie's products
address diseases with high unmet medical need and significant market

Biotie's most advanced product, Selincro(TM) (nalmefene), licensed to Lundbeck
A/S, has on 14 December 2012 received a positive opinion from the Committee
for Medicinal Products for Human Use (CHMP) of the European Medicines Agency
(EMA) recommending marketing authorization of Selincro(TM) for the reduction
of alcohol consumption in adult patients with alcohol dependence who have a
high level of alcohol consumption. In addition, Biotie has a strategic
collaboration with UCB Pharma S.A. covering tozadenant which has successfully
completed a Phase 2b study in 420 patients with advanced Parkinson's disease.
Biotie shares are listed on NASDAQ OMX Helsinki Ltd.


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Biotie Therapies Oyj via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.